| Literature DB >> 22925730 |
George C Russell1, Julio Benavides, Dawn M Grant, Helen Todd, Jackie Thomson, Vipul Puri, Mintu Nath, David M Haig.
Abstract
Malignant catarrhal fever is a lymphoproliferative disease of cattle and other ungulates caused by infection with gamma-herpesviruses of the genus Macavirus. These viruses do not establish a productive infection but instead replicate in a cell-associated fashion in T lymphocytes, leading to systemic immune dysregulation and a generally fatal outcome. Despite significant progress in understanding the pathology of this disease, its pathogenesis remains unclear. To identify genes and pathways affected in clinical MCF, sixteen bovine GeneCHIP microarrays were used to assay RNA from kidney and lymph node of four MCF-affected and four control Bos taurus steers. This is the first expression study of AlHV-1-MCF in the bovine host. Over 250 genes showed significant changes in gene expression in either lymph node or kidney, while expression of 35 genes was altered in both tissues. Pathway and annotation analysis of the microarray data showed that immune response and inflammatory genes were up-regulated in the kidney while proliferation-associated transcripts were additionally increased in the lymph node. The genes that showed the largest expression rises in both diseased tissues included cytotoxic enzymes and pro-inflammatory chemokines. These data are consistent with disease-induced stimulation of inflammatory responses involving interferon-γ, including cytotoxic T cell recruitment and activation in peripheral tissues containing virus-infected cells. However it remains unclear whether the tissue damage in MCF lesions is due entirely to the activity of infected cells or whether uninfected T cells, recruited and activated at lesion sites through the action of infected cells, contribute to the pathogenesis of MCF.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22925730 PMCID: PMC3657188 DOI: 10.1016/j.virusres.2012.08.011
Source DB: PubMed Journal: Virus Res ISSN: 0168-1702 Impact factor: 3.303
Primer and probe sequences used for quantitative PCR.
| Gene symbol | Oligonucleotide sequence (5′–3′) | Accession number of cDNA |
|---|---|---|
| RPS9-F | GCCTCGACCAAGAGCTGAAG | |
| RPS9-R | GGGCAGCCTTTCGGATCT | |
| RPS9-P | FAM-TGATCGGCGAGTATGGGCTCCG-TAMRA | |
| G6PI-F | CATTGCCTCCAAGACCTTCAC | |
| G6PI-R | GGCCGACAGGAGAAACC | |
| G6PI-P | TET-ACCCAGGAGACCATCACGAACGCA-TAMRA | |
| GNLY-F | TGGGCTGTCCTGCTCATCA | |
| GNLY-R | TCAGGAGTCAGACCGGAAAAA | |
| GNLY-P | TET-CTCGGTGCTCCTGGTTGCCCC-TAMRA | |
| GRNZH-F | GCTGGGAGAGGAGATCATTGG | |
| GRNZH-R | CAGAAACTGAACGAAAGCCATGT | |
| GRNZH-P | TET-CCAAGCCCCACTCCCGCCC-TAMRA | |
| GRNZB-F | GTAGGTGCGGTGGGTTCCT | |
| GRNZB-R | TTGATTGAGCTTCCGTTGCA | |
| GRNZB-P | TET-TCGACAGGACTTCGTGCTGACAGCC-TAMRA | |
Known genes with at least 2-fold change between MCF-affected and control tissues.
| Gene symbol | Gene title | K (FC) | K ( | LN (FC) | LN ( |
|---|---|---|---|---|---|
| GNLY | Granulysin (mean) | 8.9 | 0.0009 | 16.5 | 0.0002 |
| GZMH | Granzyme H | 10.2 | <0.0001 | 15.1 | <0.0001 |
| CXCL11 | Chemokine (C–X–C motif) ligand 11 | 14.3 | 0.0001 | 8.4 | 0.0009 |
| UBD | Ubiquitin D (mean) | 13.8 | <0.0001 | 3.2 | 0.0080 |
| CCL4 | Chemokine (C–C motif) ligand 4 | 8.8 | <0.0001 | 4.8 | 0.0002 |
| CD8A | CD8a molecule | 7.2 | <0.0001 | 2.4 | 0.0007 |
| CCL5 | Chemokine (C–C motif) ligand 5 | 5.9 | <0.0001 | 3.1 | 0.0002 |
| PLAC8 | Placenta-specific 8 (mean) | 5.8 | 0.0001 | 5.6 | 0.0014 |
| IDO1 | Indoleamine 2,3-dioxygenase 1 (mean) | 5.5 | 0.0001 | 4.9 | 0.0004 |
| CCL3 | Chemokine (C–C motif) ligand 3 (mean) | 4.9 | <0.0001 | 3.0 | 0.0008 |
| OASL | 2′–5′-oligoadenylate synthetase-like | 2.2 | 0.0058 | 3.8 | 0.0003 |
| HOPX | HOP homeobox | 3.7 | <0.0001 | 3.1 | 0.0004 |
| FCGR3A | Low affinity Fc receptor IIIa, IgG (CD16a) | 3.5 | <0.0001 | 2.2 | 0.0011 |
| WARS | Tryptophanyl-tRNA synthetase (mean) | 3.5 | <0.0001 | 2.3 | 0.0009 |
| IFNG | Interferon, gamma | 3.0 | 0.0024 | 3.3 | 0.0016 |
| RRM2 | Ribonucleotide reductase M2 polypeptide | 3.2 | 0.0010 | 2.6 | 0.0048 |
| PRF1 | Perforin 1 (pore forming protein) | 3.1 | <0.0001 | 2.4 | 0.0006 |
| CKS2 | CDC28 protein kinase regulatory subunit 2 | 2.5 | 0.0015 | 3.1 | 0.0005 |
| SH2D1A | SH2 domain protein 1A | 3.0 | <0.0001 | 2.7 | 0.0004 |
| MTHFD2 | Methylenetetrahydrofolate dehydrogenase 2 | 2.8 | 0.0003 | 2.3 | 0.0006 |
| LMNB1 | Lamin B1 | 2.3 | 0.0047 | 2.8 | 0.0010 |
| CCR5 | Chemokine (C–C motif) receptor 5 | 2.5 | 0.0001 | 2.5 | 0.0005 |
| PPA1 | Pyrophosphatase (inorganic) 1 | 2.5 | 0.0002 | 2.4 | 0.0006 |
| NCAPG | Non-SMC condensin I complex, subunit G | 2.5 | 0.0006 | 2.1 | 0.0029 |
| ISG20 | Interferon stimulated exonuclease gene 20 kDa | 2.5 | 0.0012 | 2.4 | 0.0016 |
| CDCA8 | Cell division cycle associated 8 | 2.5 | 0.0005 | 2.2 | 0.0017 |
| NUSAP1 | Nucleolar and spindle associated protein 1 | 2.4 | 0.0021 | 2.1 | 0.0057 |
| CD96 | CD96 molecule | 2.4 | 0.0003 | 2.4 | 0.0006 |
| TOP2A | Topoisomerase (DNA) II alpha 170 kDa (mean) | 2.4 | 0.0077 | 2.1 | 0.0090 |
| UBE2C | Ubiquitin-conjugating enzyme E2 C | 2.3 | 0.0004 | 2.2 | 0.0009 |
| CCNB2 | Cyclin B2 | 2.1 | 0.0051 | 2.1 | 0.0032 |
| CRELD2 | Cysteine-rich with EGF-like domains 2 | 2.0 | 0.0070 | 2.1 | 0.0048 |
Gene identities for probesets from the Affymetrix GeneChip Bovine Genome Arrays were obtained from the NetAffx™ Analysis Center (www.affymetrix.com/analysis/index.affx) or were assigned following sequence-based database searching.
Genes are ordered on the basis of their maximal expression change in either tissue.
Fold-change in gene expression (FC) in MCF compared to control tissue, and p-values adjusted for false discovery rate (p) are listed for kidney (K) and lymph node (LN) samples.
False discovery rate adjusted p-values (p) are expressed with 4-decimal precision.
Where multiple probesets representing the same gene were significantly altered in expression, the FC value given is the mean, indicated in the gene name column, while the p value shown is the highest of the probesets analysed.
Degree of down-regulation is expressed as the inverse of the fold-change (1/FC).
Fig. 1Gene expression fold-change values derived from qPCR data. The changes in expression of four genes: glucose-6-phosphate isomerase (GPI); granulysin (GNLY); granzyme B (GZMB); and granzyme H (GZMH) in MCF-affected tissues were normalised to ribosomal protein S9 (RPS9) and plotted with respect to equivalent tissues from control animals. Results of kidney transcript assays are in the light columns while results of lymph node assays are in the dark columns.
DAVID software analysis.
| Annotation type | Kidney | Score | Lymph node | Score | ||
|---|---|---|---|---|---|---|
| Up-regulated annotation clusters | Antigen processing and presentation | 6.0 | Cell division | 6.2 | ||
| Inflammatory response | 5.8 | Mitosis, cell cycle | 2.8 | |||
| Regulation of immune response | 5.3 | Chemokines and receptors | 2.4 | |||
| Regulation of lymphocyte mediated immunity | 3.6 | Autoimmune reaction | 2.4 | |||
| Regulation of lymphocyte activation | 3.5 | Meiosis | 2.0 | |||
| Up-regulated KEGG pathways | Antigen processing and presentation | <0.0001 | Meiosis | 0.0001 | ||
| Allograft rejection | <0.0001 | Graft- | 0.0013 | |||
| Graft- | <0.0001 | Cell cycle | 0.0018 | |||
| Viral myocarditis | <0.0001 | Allograft rejection | 0.0018 | |||
| Cell adhesion molecules | <0.0001 | Cytokine-receptor interaction | 0.0020 | |||
| Down-regulated annotation clusters | Short-chain dehydrogenase/reductase | 2.0 | Cell adhesion | 3.0 | ||
| Follistatin-like proteins | 2.5 | |||||
| Protein phosphatase binding | 2.1 | |||||
| Embryonic development | 1.5 | |||||
| Membrane organisation | 1.4 | |||||
| Down-regulated KEGG pathways/GO terms | GO:0055114 oxidation-reduction | <0.0001 | Cell adhesion molecules | 0.001 | ||
| GO:0045833 regulation of lipid metabolic process | 0.0047 | Cardiomyopathy | 0.005 | |||
| GO:0005932 microtubule basal body | 0.0068 | |||||
Enriched annotation terms among genes with altered regulation (based on genes with p < 0.01 and FC > 2 from the microarray analysis). In each annotation type the top five entries with score > 1 or p < 0.01 are shown.
The significance of enrichment was measured by the score, the geometric mean (−log) of the p-values of the contributing genes, or by the p-value.
p-values were derived by a modified Fisher's exact test.
No significant enrichment of genes in KEGG pathways was seen among down-regulated genes in the kidney, so the most significantly enriched gene ontology (GO) terms (p < 0.01) are given for this gene set.
Pathway analysis (IPA, based on all probesets).
| Classification | Kidney | Score | Molecules | Lymph node | Score | Molecules | ||
|---|---|---|---|---|---|---|---|---|
| Top networks | Cellular assembly and organisation; genetic disorder; ophthalmic disease. | 37 | RNA post transcriptional modification; protein synthesis; small molecule biochemistry. | 37 | ||||
| Antigen presentation; inflammatory response; genetic disorder. | 35 | Cell cycle; developmental disorder; genetic disorder. | 37 | |||||
| DNA replication, recombination and repair; cellular assembly and organisation; cell–cell signalling and interaction. | 35 | Cancer; cell cycle; cellular growth and proliferation. | 33 | |||||
| Amino acid metabolism; protein synthesis; small molecule biochemistry. | 31 | Cellular movement; nervous system development and function; cell morphology. | 32 | |||||
| Cellular development; haematological system development and function; haematopoiesis. | 31 | Protein trafficking, RNA post-transcriptional modification, molecular transport. | 32 | |||||
| Top diseases/disorders | Inflammatory response. | 0.0006 | 217 | Cancer. | 0.021 | 659 | ||
| Immunological disease. | 0.0006 | 270 | Genetic disorder. | 0.020 | 247 | |||
| Inflammatory disease. | 0.0006 | 292 | Respiratory disease. | 0.001 | 113 | |||
| connective tissue disorders. | 0.0001 | 200 | Gastrointestinal disease. | 0.020 | 239 | |||
| skeletal and muscular disorders. | 0.0002 | 275 | Reproductive system disease. | 0.020 | 367 | |||
| Top molecular functions | Cellular growth and proliferation. | 0.0005 | 254 | Cell cycle. | 0.021 | 291 | ||
| Cellular development. | 0.0006 | 215 | Cellular assembly and organisation. | 0.014 | 79 | |||
| Cellular function and maintenance. | 0.0005 | 136 | DNA replication, recombination and repair. | 0.019 | 164 | |||
| Cell death. | 0.0004 | 292 | Cellular movement. | 0.020 | 191 | |||
| Cell–cell signalling and interaction. | 0.0005 | 207 | Antigen presentation. | 0.014 | 33 | |||
| Top canonical pathways | Antigen presentation. | <0.0001 | 16/43 | Mitochondrial dysfunction. | <0.0001 | 42/169 | ||
| CD28 signalling in Th cells. | <0.0001 | 33/135 | Protein ubiquitination pathway. | <0.0001 | 66/274 | |||
| iCOS–iCOSL signalling in T helper cells. | <0.0001 | 27/125 | Ubiquinone biosynthesis. | <0.0001 | 26/119 | |||
| Natural Killer cell signalling. | <0.0001 | 25/116 | Mitotic roles of polo-like kinase. | <0.0001 | 21/63 | |||
| Systemic Lupus Erythematosus signalling. | <0.0001 | 25/125 | Cell cycle control of chromosomal replication. | <0.0001 | 14/31 | |||
The score (integer; negative log of respective IPA p-value) or maximum p-value assigned by the IPA software for each classification is given. IPA uses a right tailed Fisher's exact test to calculate p-values.
The number of molecules with significantly altered expression assigned to each classification from the submitted gene lists or the number of genes/total number of molecules in pathway.